Review Article

The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck

Table 4

Summary of alternative Anti-EGFR monoclonal antibodies.

StudyYearPhaseAgentNumber of Patients/agentResponse (%)/Survival (months)

Locally advanced

Antibody + radiation

Crombet et al. [31]2004I/IINimotuzumab CR 56
DCR 88
3 yr OS 67
Rojo et al. [32]2010INimotuzumab CR 20
PR 70
SD 10
DCR 90
Rodríguezet al. [33]2010IINimotuzumab CR 60
OS 12.5 mo
Babu et al. [34]2010IINimotuzumab 4 yr OS 34

Antibody + chemoradiation

Wirth et al. [35] 2010IPanitumumab ; paclitaxel/
carboplatin
CR 69
PR 31
SD 0
DCR 100
Gupta and Madholia [36]2010INimotuzumab ; weekly cisplatin
CR 59
PR 18
SD 12
DCR 89
Babu et al. [34]2010IINimotuzumab ; cisplatin4 yr OS 47

Palliative

Vermorken et al. [37] (SPECTRUM)2010IIIPanitumumab ; platinum therapy/5-FUORR 36 versus 25
PFS 5.8 versus 4.6
OS 11.1 versus 9.0
Machiels et al. [38]
2011IIIZalutumumab ; optional methotrexateDCR 48 versus 27
ORR 6.3 versus 1.1
PFS 2.5 versus 2.1
OS 6.7 versus 5.2
Guo et al. [39]2011INimotuzumab ; cisplatin/docetaxel/5-FUCR 6
PR 55
SD 25
DCR 86

CR: complete response, PR: partial response, SD: stable disease, DCR: disease control rate (CR + PR + SD), ORR: overall response rate, PFS: progression-free survival, and OS: overall survival; *statistically significant; **high-dose treatment group.